Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Sarepta Therapeutics Inc (SRPT)  
$123.46 3.67 (2.89%) as of 4:30 Fri 5/24


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 84,190,000
Market Cap: 10.39(B)
Last Volume: 427,350 Avg Vol: 426,179
52 Week Range: $67.31 - $141.53
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  983
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 143,757 247,027
Total Buy Value $0 $0 $13,295,068 $24,257,422
Total People Bought 0 0 3 3
Total Buy Transactions 0 0 5 7
Total Shares Sold 27,731 27,731 42,731 43,589
Total Sell Value $3,499,041 $3,499,041 $5,099,841 $5,194,152
Total People Sold 7 7 7 7
Total Sell Transactions 7 7 8 9
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 360
  Page 12 of 15  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ingram Douglas S President & CEO   •       •      –    2017-07-27 4 B $42.50 $1,999,965 D/D 47,058 382,058 2.81     -
   Mahatme Sandesh EVP, CFO & CBO   •       –      –    2017-07-21 4 OE $23.85 $35,775 D/D 1,500 33,861     -
   Howton David T SVP, General Counsel   •       –      –    2017-07-21 4 OE $13.71 $20,565 D/D 1,000 23,301     -
   Ruff Shamim SVP, Regulatory Affairs & Qual   •       –      –    2017-07-21 4 S $44.00 $66,000 D/D (1,500) 21,062     -
   Ruff Shamim SVP, Regulatory Affairs & Qual   •       –      –    2017-07-21 4 OE $13.90 $83,133 D/D 5,888 22,562     -
   Ruff Shamim SVP, Regulatory Affairs & Qual   •       –      –    2017-07-21 4 AS $44.00 $193,072 D/D (4,388) 21,062     -
   Mahatme Sandesh EVP, CFO & CBO   •       –      –    2017-07-20 4 AS $41.00 $2,050,000 D/D (50,000) 32,361     -
   Mahatme Sandesh EVP, CFO & CBO   •       –      –    2017-07-20 4 OE $13.71 $769,107 D/D 50,000 39,988     -
   Howton David T SVP, General Counsel   •       –      –    2017-07-20 4 AS $41.00 $1,025,000 D/D (25,000) 22,301     -
   Howton David T SVP, General Counsel   •       –      –    2017-07-20 4 OE $13.71 $342,750 D/D 25,000 28,245     -
   Ruff Shamim SVP, Regulatory Affairs & Qual   •       –      –    2017-07-20 4 AS $42.00 $262,500 D/D (6,250) 21,062     -
   Ruff Shamim SVP, Regulatory Affairs & Qual   •       –      –    2017-07-20 4 OE $13.71 $85,688 D/D 6,250 27,312     -
   Cumbo Alexander SVP, Chief Commercial Officer   •       –      –    2017-07-20 4 AS $41.00 $242,638 D/D (5,918) 16,875     -
   Cumbo Alexander SVP, Chief Commercial Officer   •       –      –    2017-07-20 4 OE $13.71 $34,275 D/D 2,500 22,793     -
   Kaye Edward M. Md Director   –       •      –    2017-07-20 4 AS $41.00 $410,000 D/D (10,000) 52,471     -
   Kaye Edward M. Md Director   –       •      –    2017-07-20 4 D $40.93 $178,005 D/D (4,349) 62,471     -
   Ingram Douglas S President & CEO   •       •      –    2017-06-26 4 A $0.00 $0 D/D 335,000 335,000     -
   Kaye Edward M. Md President & CEO   •       •      –    2017-04-20 4 D $32.54 $141,516 D/D (4,349) 66,820     -
   Mahatme Sandesh EVP, CFO & CBO   •       –      –    2017-03-19 4 D $30.30 $5,181 D/D (171) 32,361     -
   Howton David T SVP, General Counsel   •       –      –    2017-03-19 4 D $30.30 $4,606 D/D (152) 22,301     -
   Ruff Shamim SVP, Regulatory Affairs & Qual   •       –      –    2017-03-19 4 D $30.30 $5,363 D/D (177) 21,062     -
   Nicaise Claude Director   –       •      –    2017-03-10 4 A $0.00 $0 D/D 1,000 2,000     -
   Wigzell Hans Lennart Rudolf Director   –       •      –    2017-03-10 4 A $0.00 $0 D/D 1,000 6,666     -
   Kress Jean-Paul Director   –       •      –    2017-03-10 4 A $0.00 $0 D/D 1,000 2,000     -
   Behrens M Kathleen Director   –       •      –    2017-03-10 4 A $0.00 $0 D/D 1,000 113,116     -
  360 Records found
  Previous  10  11  12  13  14  15   
  Page 12 of 15
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us